Drug intelligence / Profile preview

177-Lu-DOTA-cG250

Development stage: Phase 2
Lead developer: Telix Pharmaceuticals
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

177-Lu-DOTA-cG250 is a radiolabeled chimeric monoclonal antibody targeting carbonic anhydrase IX (CAIX), a protein highly expressed in renal cell carcinoma. The drug consists of the cG250 antibody conjugated to the chelator DOTA and labeled with the beta-emitting radionuclide lutetium‑177. Upon administration, it binds specifically to CAIX-expressing tumor cells and delivers targeted ionizing radiation to induce tumor cell death while sparing surrounding healthy tissue. It is being developed primarily for advanced or metastatic renal cell carcinoma and has been evaluated in phase I/II clinical trials for safety, dosimetry, and preliminary efficacy[1][2][5][8].

Brand names: TLX250TLX-250TLX 250
Other names: 177-Lutetium-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-cG250Lu-177-DOTA-girentuximabLu177-DOTA-girentuximabLu 177-DOTA-girentuximabTLX-250TLX250TLX 250

Targets

CA9 (Carbonic anhydrase IX)

Beyond the preview

Go deeper on 177-Lu-DOTA-cG250.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 177-Lu-DOTA-cG250.

Explore the full profile